Quanterix™
The Science of Precision Health

Simoa® Total IL-22 Discovery Kit
HD-1/HD-X Data Sheet

Item 103071

Description

IL-22 is a member of the IL-10 superfamily of cytokines. These cytokines are pleiotropic, affecting a wide range of immune functions. IL-22 is produced by Dendritic, T, and Innate Lymphoid cells and can be found in a wide range of tissues. Biological activity of IL-22 is initiated through interactions with IL-22R1 and IL-10R2, as well as IL-22BP1 and is regulated by IL-17A. IL-22 activation plays a role in the initiation and regulation of nonspecific immune response. IL-22 is associated with psoriasis; serum levels of the cytokine correlate with the severity of the disease. Emerging evidence suggests that IL-22 can play a role in other autoimmune disorders such as Inflammatory Bowel Disease, Rheumatoid Arthritis, and Multiple Sclerosis, perhaps due to its role in inflammatory responses, which are regulated by IL-17A. IL-22 has also been implicated as a Reg gene regulator promoting β-cell production in Type 1 diabetes. The Total IL-22 Discovery assay detects free IL-22 and IL-22 bound to IL-22BP.

Calibration Curve: Calibrator concentrations and Lower Limit of Quantification depicted.



Lower Limit of Quantification (LLOQ): Triplicate measurements of serially diluted calibrator were read back on the calibration curve for 5 runs each for 1 reagent lot on a single instrument (5 runs total). The LLOQ is determined as the lowest dilution with a pooled CV ≤ 20% and sample concentration recovery between 80-120% of the expected.

Limit of Detection (LOD): Calculated as 2.5 standard deviations from the mean of background signal read back on each calibration over 5 runs for 1 reagent lot on a single instrument (5 runs total).

LLOQ	**0.0103 pg/mL** pooled CV 9% mean recovery 120%
LOD	**0.0054 pg/mL** range 0.0026-0.0090 pg/mL
Dynamic range	0–120 pg/mL
Sample volume	80 µL Minimum for 2 reps
Tests per kit	192

Endogenous Sample Reading: Healthy donor matched EDTA plasma (n=10) and serum (n=10) samples were measured. Bars depict median with interquartile range.



Matched human samples (n=10)	Mean IL-22 pg/mL	Median IL-22 pg/mL	% Above LOD
EDTA plasma	9.19	7.82	100%
Serum	8.44	7.16	100%

Quanterix Corporation
900 Middlesex Turnpike, Billerica, MA 01821
techsupport@quanterix.com

Precision: Measurements of 3 serum or plasma-based panels. Triplicate measurements were made for 5 runs using 1 reagent lot and a single instrument (5 runs total, 15 measurements).

Sample	Mean (pg/mL)	Within run CV	Between run CV
Panel 1	0.834	8.2%	4.7%
Panel 2	6.10	6.1%	7.4%
Panel 3	20.3	5.4%	7.0%

Spike and Recovery: 2 EDTA plasma and 4 serum samples were spiked at high and low concentrations within the range of the assay.

Dilution Linearity: 1 endogenous EDTA plasma and 1 endogenous serum sample were serially diluted 2x serially from MRD (4x) to 256x with Sample Diluent.

Spike and Recovery (Serum/Plasma)	**97%** Range 86-119%
Plasma Dilution Linearity (256x)	**Mean = 117%** Range: 107-128%
Serum Dilution Linearity (256x)	**Mean = 115%** Range: 104-124%

Specificity: Two normal serum samples and one normal plasma sample were pre-incubated with 100X capture antibody. Antibody was removed and samples were run at MRD in the assay. Average knock-down relative to control without pre-incubation was **100%**.

The Simoa Total IL-22 Discovery assay kit is formulated for use on the SR-X®, HD-1, or HD-X® platform. Data in this document was obtained from runs on the HD-1 platform unless otherwise noted. Some differences in performance claims between SR-X and HD-1/HD-X may be observed when comparing datasheets for these platforms. This may be due to experiments run at different time-points with different reagent lots and different samples, or it may be due to minor differences in antibody and analyte behavior in the different assay formats.

Quanterix Corporation
900 Middlesex Turnpike, Billerica, MA 01821
techsupport@quanterix.com